

To, BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 6th November, 2020

Scrip Code: 540108 Scrip Symbol: TAHL

Sub: Outcome of Board Meeting held on 6th November, 2020

Dear Sir,

The Board of Directors of the Company at its Meeting held today i.e. 6th November, 2020 inter alia has transacted, adopted and approved the following:

- 1) The Standalone Un-audited Financial Results for the Quarter and half Year ended on 30th September, 2020 as per Regulation 33 of SEBI (LODR) Regulation, 2015 with Limited Review Report of Statutory Auditors of the Company.
- 2) Appointment of Mr. Naresh Veeramalla, as a Non-Executive Independent Director on the Board of Directors of the Company w.e.f. November 06, 2020 to hold office for a term upto 5 (Five) consecutive years subject to the approval of the members in the ensuing General Meeting.
- 3) Change in Designation of Mr. Dasarath Kumar Kallur from Non-Executive Non-Independent Director to Executive Director on the Board of Directors of the Company w.e.f. November 06, 2020 to hold office for a term of upto 3 (Three) consecutive years subject to the approval of the members in the ensuing General Meeting.
- 4) Appointment of Mr. Dasarath Kumar Kallur as the Chief Financial Officer of the Company w.e.f. November 07, 2020.
- 5) Change of Corporate Office to Office No. B1, 2nd Floor, Padam Manohar Arcade, Beside More Supermarket, Opp. Sainath Hospital, Madhura Nagar, S.R Nagar, Hyderabad, 500038, Telangana.

The Board has noted the Resignation of Tansukh Lal Badara as Executive Director and the Resignation of Vinod Jaigopal Sharda as the Chief Financial Officer of the Company w.e.f 6th November, 2020.

The Meeting of Board of Directors of the Company commenced at 6:00 p.m. and concluded at 07:55 p.m.

For Tiaan Ayurvedic & Herbs Limited

Sudharshan Rangarajan Managing Director



Particulars Quarter Ended Grown Fall Fall	Statement of Un-Audited Financial Results for the Quarter & Six Months ended 30th September, 2020							
	Donti culono		Ou outou En do d		Half Van			
Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited (Unaudited Audited Levenue from operations 19,955,094 11,500,000 80,409,720 31,455,094 129,255,490 191,308,110	Particulars	30/09/2020		30/09/2019				
Revenue from operations		30,03,2020	30,00,2020	30/03/2013	30/03/2020	00/03/2013	01/00/2020	
II. Other income				(Unaudited)				
III. Total Revenue (I + II)	I. Revenue from operations	19,955,094	11,500,000	80,409,720	31,455,094	129,255,490	191,388,110	
No. No.	II. Other income	245,000	102,630	0.00	347,630	10,703	821,456	
Cost of materials consumed 0.00	III. Total Revenue (I + II)	20,200,094	11,602,630	80,409,720	31,802,724	129,266,193	192,209,566	
Description of Stock-in-Trade 14,450,521 4,023,563 71,164,651 18,474,084 113,760,312 164,617,070	IV. Expenses:							
Changes in inventories of finished goods work-in-progress and Stock-in-Trade 125,885 0.00 125,885 0.00 4,354,021	Cost of materials consumed	0.00	0.00	0.00		0.00	0.00	
Changes in inventories of finished goods work-in-progress and Stock-in-Trade 125,885 0.00 125,885 0.00 4,354,021	Purchases of Stock-in-Trade	14,450,521	4,023,563	71,164,651	18,474,084	113,760,312	164,617,070	
In-Trade	Changes in inventories of finished	, , -	,,	, - ,	-, ,	-, -,-	, , , , , , , , , , , , , , , , , , , ,	
Employee benefits expense			425.005	0.00	425.005	0.00	4.25.4.024	
Finance Costs	in-Trade	-	·	0.00	125,885	0.00	4,354,021	
Depreciation and amortisation expense 539,942 539,942 539,942 539,942 1,079,884 1,330,457 2,410,341 Other expenses 500,530 1,543,060 997,738 2,043,590 1,878,369 4,995,846 Total expenses 15,903,993 7,588,750 73,726,951 23,366,858 118,834,467 180,955,207 V. Profit before exceptional items 0.00 0.00 0.00 0.00 0.00 0.00 VI. Exceptional items 0.00 0.00 0.00 0.00 0.00 0.00 VII. Profit before exceptional items 0.00 0.00 0.00 0.00 0.00 0.00 VII. Profit before exceptional items and tax (V - VI) 4,296,101 4,013,880 6,682,769 83,09,981 10,431,726 11,254,359 VIII. Tax expense:	Employee benefits expense	413,000	1,356,300	1,024,620	1,769,300	1,865,329	4,577,929	
Exceptional tems 539,942 539,942 539,942 1,079,884 1,330,457 2,410,341		0.00	0.00	0.00	0.00	0.00	0.00	
Total expenses 15,903,993 1,543,060 997,738 2,043,590 1,878,369 4,995,846		539,942	539,942	539,942	1,079,884	1,330,457	2,410,341	
Total expenses 15,903,993 7,588,750 73,726,951 23,366,858 118,834,467 180,955,207		·		·				
V. Profit before exceptional items and tax (III - IV)	•							
Items and tax (III - IV)	•	13,903,993	7,300,730	73,720,931	23,300,030	110,034,407	100,933,207	
VII. Profit before exceptional items and tax (V - VI)		4,296,101	4,013,880	6,682,769	83,09,981	10,431,726	11,254,359	
Items and tax (V - VI)	VI. Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	
VIII. Tax expense:			4 0 4 0 0 0 0		00.00.004	40 404 704	44.054.050	
(1) Current tax	items and tax (V - VI)	4,296,101	4,013,880	6,682,769	83,09,981	10,431,726	11,254,359	
C2 Deferred tax	VIII. Tax expense:							
IX. Profit (Loss) for the period from continuing operations (VII-VIII) 3,292,631 3,010,410 4,945,249 6,303,041 7,756,967 8,352,719	(1) Current tax	1,003,470	1,003,470	1,737,520	2,006,940	2,674,759	2,901,640	
Section Sect		0.00	0.00	0.00	0.00	0.00	0.00	
(VII-VIII) 3,292,631 3,010,410 4,945,249 6,303,041 7,756,967 8,352,719 X. Profit/(loss) from								
X. Profit/(loss) from discontinuing operations 0.00		3 202 631	3 010 410	4 945 249	6 303 041	7 756 967	8 352 719	
XI. Tax expense of discontinuing operations 0.00 0.0		3,272,031	3,010,410	1,713,217	0,303,041	7,730,707	0,332,717	
Operations O.00 O		0.00	0.00	0.00	0.00	0.00	0.00	
XII. Profit/(loss) from Discontinuing operations (after tax) (X-XI)		0.00	0.00	0.00	0.00	0.00	0.00	
Discontinuing operations (after tax) (X-XI)		0.00	0.00	0.00	0.00	0.00	0.00	
XIII. Other Comprehensive Income A. (i) Items that will not be reclassified to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 0.00								
A. (i) Items that will not be reclassified to profit or loss 0.00		0.00	0.00	0.00	0.00	0.00	0.00	
A. (i) Items that will not be reclassified to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	-							
reclassified to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0								
that will not be reclassified to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0	reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	
profit or loss 0.00								
B. (i) Items that will be reclassified		0.00	0.00	0.00	0.00	0.00	0.00	
		0.00	0.00	0.00	0.00	0.00	0.00	
	to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will be reclassified to profit or								
loss 0.00 0.00 0.00 0.00 0.00 0.00	•	0.00	0.00	0.00	0.00	0.00	0.00	



(Formerly known as Rachana Capital & Securities Ltd)

XIV. Total Comprehensive Income for the period (XIII+XIV) Comprising profit(loss) and other comprehensive Income for the period) Paid-up Share Capital	3,292,631 64,585,000	3,010,410 51,668,000	4,945,249 51,668,000	6,303,041 64,585,000	7,756,967 51,668,000	8,352,719 51,668,000
XV. Earnings per equity share:						
(1) Basic	0.51	0.58	0.957	0.97	1.501	1.62
(2) Diluted	0.51	0.58	0.957	0.97	1.501	1.62

Notes:

- The Standalone Un-Audited Financial Results of the Company for the Quarter and Half Year ended on 30th
 September, 2020 have been reviewed by the Audit Committee and taken on record by the Board of
 Directors at their meeting held on 06.11.2020
- The Limited Review of Un-Audited Financial Results for the Quarter and Half year ended September 30, 2020 as required in terms of Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015 has been carried out by Statutory Auditors.
- 3. Previous year/period figures have been regrouped/rearranged wherever necessary to make them Comparable with current period figures.
- 4. The Company has only One Reportable Segment i.e. Ayurvedic & Herbs Products.
- 5. The Board of Directors at its meeting held on 06 March, 2020 recommended issue of one bonus share for every four equity shares held by the equity shareholders. The shareholders approved such issue of bonus shares on June 25, 2020. Accordingly on July 08, 2020, 12,91,700 equity shares of INR 10/- each as fully paid up were allotted to the members on the record date July 03, 2020.

Further, the Company has transferred a sum equal to the nominal value of the shares so issued, i.e., INR 1,29,17,000/- lakhs from reserves and Surplus. Consequently, the earnings per share data for the quarter and half year ended September 30, 2020 adjusted accordingly.

For Tiaan Ayurvedic & Herbs Limited

Rangarajan Sudharshan Managing Director

Date: 06.11.2020 Place: Vadodara



PARTICULARS	AS AT 30-09-20	AS AT 31-03-20
	(UNAUDITED)	(AUDITED)
ASSETS		
Non-Current Assets		
(a) Property, Plant, Equipment	7,535,429	8,615,313
(b) Capital Work-in-progress	0.00	0.00
(c)Investment	0.00	0.00
(d) Goodwill	0.00	0.00
(e) Other Intangible Assets	0.00	0.00
Non-Current Financial Assets		
(f) Non currentInvestments	7,500,000	7,500,000
(g) Trade Receivables	0.00	0.00
(h) Loans and Advances	19,665,920	19,665,920
(i) Deferred Tax Assets (Net)	0.00	0.00
(j) Other Non-current Assets	0.00	0.00
Total Non-Current Assets	34,701,349	35,781,233
Current Assets		
(a) Inventory	32,428,552	32,428,552
(b) Financial Assets		
(i) Investment	0.00	0.00
(ii) Trade Receivables	81,538,399	98,902,702
(iii) Cash and Cash equivalents	223,862	2,68,870
(iv) Bank balance	144,481	0.00
(iv) Loans	0.00	0.00
(v) Other Financial Assets	0.00	0.00
(c) Other Current Assets	4,529,910	1,633,715
Total Current Assets	118,865,204	133,233,839
Total Assets	153,566,553	169,015,072
EQUITY AND LIABILITIES	, ,	, , ,
Equity		
(a) Equity Share Capital	64,585,000	51,668,000
(b) Reserves	39,506,618	46,120,577
Total Equity	104,091,618	97,788,577
Liabilities	, ,	, ,
Non-Current Liabilities		
a) Financial Liabilities		
(i) Borrowings	0.00	0.00
(ii) Deferred Tax Liabilities (net)	0.00	0.00
(iii) Trade Payables	32,278,867	57,637,367
(iv) Provisions	13,759,470	11,752,530
(v) Other Non-Current Liabilities	3,436,598	1,836,598
Total Liabilities	49,474,935	71,226,495
Total Equity and Liabilities	153,566,553	169,015,072

For Tiaan Ayurvedic & Herbs Limited

Rangarajan Sudharshan Managing Director

Date: 06.11.2020 Place: Vadodara



TIAAN AYURVEDIC & HERBS LIMITED

Cash Flow Statement for the Half Year Ended on 30^{th} September, 2020

Amount in Rs.

	Half Year Ended 30.09.2020	Half Year Ended 30.09.2019
(A): CASH FLOW FROM OPERATING ACTIVITIES:	3010712020	30.07.2017
Net Profit after taxation and extraordinary items	6303041	7756967
Adjustment for :		
Depreciation	1079884	1330455
Interest Expenses		
Profit on sale of Fixed Assets		
Gross Income	(31802724)	(129266193)
Operating Profit before Working Capital changes	(24419799)	(120178771)
Adjustment for working capital changes :		
Movement in Working Capital		
(Increase) / Decrease in Trade Receivables	17364303	(1207358)
(Increase) / Decrease in short term loan	-	(281760)
(Increase) / Decrease in other Current Assets	(2896195)	175387
(Increase) / Decrease in current finance assets		
(Increase) / Decrease other assets		
(Increase) / Decrease in Inventory		(13166672)
(Increase) / Decrease in long term loans & Advances		
Increase / (Decrease) in Current Liabilities & Provisions	(21751560)	5388867
NET CASH GENERATED FROM OPERATING ACTIVITIES	(7283452)	(9091536)
(B): CASH FLOW FROM INVESTING ACTIVITIES:		
(Increase) / Decrease in Investments		
Gross Income	31802724	129266193
Addition / Purchase of Fixed Assets		
Sale proceeds of Fixed Assets		
Other Non-Current Assets		
NET CASH GENERATED FROM INVESTING ACTIVITIES	31802724	129266193
(C): CASH FLOW FROM FINANCING ACTIVITIES:		
Interest Expenses		
Proposed Dividend		
Issue / Reduction of Share capital	12917000	
Increase/Decrease in Reserve &premium account	(12917000)	



(Formerly	known	as	Rachana	Capital	&	Securities	Ltd)

NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	99473	(4114)
(A+B+C)		

Cash Equivalents at the beginning	268870	277465
Cash Equivalents at the End Period	368343	273351

For Tiaan Ayurvedic & Herbs Limited

Rangarajan Sudharshan Managing Director

Date: 06.11.2020 Place: Vadodara





LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF TIAAN AYURVEDIC & HERBS LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

Review Report to the Board of Directors, Tiaan Ayurvedic & Herbs Limited

We have reviewed the accompanying statement of Standalone Un-audited Financial Results of Tiaan Ayurvedic & Herbs Limited ("the Company") for the quarter and half year ended 30th September, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our Responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mehul M. Shah & Co.

Chartered Accountants

Mehul M Shah

F.R No.: 141907W Membership No.: 044044

UDIN: 20044044AAAABU4939

MUMBA

ered Acco

Date: 06/11/2020 Place: Mumbai